PCP ELISA Kit

Name: PCP ELISA Kit
SKU: DEIA4027
Rating: 5 (1 reviews)

Regulatory status: For research use only, not for use in diagnostic procedures.

COA

SDS

Datasheet

Summary

Sample

Urine, Blood, Oral Fluid, Breast Milk

Species Reactivity

Human; Research Animal

Detection Method

cELISA

Intended Use

For the determination of trace quantities of PCP in human urine, blood, or oral fluid.

Contents of Kit

1. EIA Buffer: 30 mL (ready-to-use). Phosphate buffered saline solution with bovine serum and a preservative. Provided for dilution of samples.
2. Wash Buffer Concentrate (10×): 20 mL. Phosphate buffered saline solution with a surfactant. Dilute 10 fold with deionized or ultrapure water before use. Diluted wash buffer is used to wash all unbound conjugate and samples from the plate after the conjugate incubation.
3. Substrate: 20 mL (ready-to-use). Stabilized 3, 3', 5, 5' Tetramethylbenzidine (TMB) plus Hydrogen Peroxide (H₂O₂) in a single bottle. It is used to develop the color in the wells after washing. Light sensitive.
4. Drug-Enzyme Conjugate: 14 mL (ready-to-use). Drug-horseradish peroxidase conjugate. Do not dilute.
5. Antibody Coated Plate: A 96 well Costar plate, in strips of 8 break-away wells, coated with anti-drug antiserum. The plate is ready for use as is. Do not wash.
6. Acid Stop Solution: 14 mL (ready-to-use). 1 N H₂SO₄ used to stop the enzyme reaction.
7. Whole Blood Cut-off Calibrators: DO NOT DILUTE.
a. Blood Negative Calibrator: 1 mL provided in a synthetic matrix (red cap).
b. Blood Cut-off Calibrator- (PCP): 1 mL provided in a synthetic matrix, 10 ng/mL (red cap).
8. Urine Cut-off Calibrators: DO NOT DILUTE.
a. Urine Negative Calibrator: 1 mL provided in a synthetic matrix (yellow cap).
b. Urine Cut-off Calibrator- (PCP): 1 mL provided in a synthetic matrix, 25 ng/mL (yellow cap).
9. Oral Fluid Cut-off Calibrators: DO NOT DILUTE.
a. Oral Fluid Negative Calibrator: 1 mL provided in a synthetic matrix (clear cap).
b. Oral Fluid Cut-off Calibrator- (PCP): 1 mL provided in a synthetic matrix, 10 ng/mL (clear cap).

Storage

This kit can be used until the expiration date on the label when stored refrigerated at 2-8°C.

Sensitivity

The term I-50 is used to define the sensitivity of the test. This number is derived from a standard curve generated with the drug. The drug concentration that shows 50% less color activity than the zero standard is considered to be the I-50.

General Description

Creative Diagnostics's PCP (RTU) ELISA Kit is a qualitative one-step kit designed for use as a screening device for the detection of drugs and/or their metabolites. The kit was designed for screening purposes and is intended for research use only. It is recommended that all suspect samples be confirmed by a quantitative method such as gas chromatography/mass spectrometry (GC/MS).

Standard Curve

Citations

Have you cited DEIA4027 in a publication? Let us know and earn a reward for your research.

Documents

pdf COA

pdf SDS

pdf Datasheet

QA & Reviews

Customer Reviews

References

Synthesis and antinociception properties of phencyclidine derivatives with modified aromatic or cycloalkyl rings and amino group

MONATSHEFTE FUR CHEMIE

Authors: Ahmadi, Abbas; Khalili, Mohsen; Barzin, Mahnaz; Pooladi, Mohsen; Bakhtiari, Fatemeh; Barjeste, Maede; Nahri-Niknafs, Babak

Abstract

Phencyclidine is an arylcyclohexylamine compound which has received a lot of investigative attention due to the complex spectrum of behaviours and its complicated interactions with the central nervous system. Phencyclidine administration may act as stimulant, depressant, hallucinogen, and analgesic depending on dose and tested species. In this study, new phenyl and thienyl analogues with specific affinity for the phencyclidine sites in NMDA receptors, dopamine uptake blocking, or both of them were synthesized. The acute and chronic pain properties of these compounds were studied using the tail immersion and formalin tests on mice and the results were compared with control and phencyclidine groups at a dose of 10 mg/kg. The outcomes indicated that all synthesized compounds showed better activities to decrease acute thermal and chemical, but not chronic pains. Also, these effects were more significant for phenyl (group 1) compared to thiophene (group 2) analogues, which is probably due to the higher affinity of group 1 for inhibition of dopamine reuptake compared to binding to the phencyclidine sites in NMDA receptors in this family. [GRAPHICS] .

Selective adrenergic alpha2C receptor antagonist ameliorates acute phencyclidine-induced schizophrenia-like social interaction deficits in rats

PSYCHOPHARMACOLOGY

Authors: Savolainen, Katja; Ihalainen, Jouni; Jalkanen, Aaro J.; Forsberg, Markus M.

Abstract

RationaleSocial withdrawal is a core feature of the negative symptoms of schizophrenia. Currently available pharmacotherapies have only limited efficacy towards the negative symptoms, i.e., there is a significant unmet medical need in the treatment of these symptoms.ObjectiveWe wanted to confirm whether selective adrenergic (2C) receptor (AR) antagonist therapy could ameliorate acute phencyclidine (PCP)-induced schizophrenia-like social interaction deficits in rats, and to compare the effects of an (2C) AR antagonist to another putative therapeutic alternative, an (7) nicotinic acetylcholine receptor (nAChR) partial agonist, as well against three commonly used atypical antipsychotics.MethodsHere, we used acute PCP administration and modified a protocol for testing social interaction deficits in male Wistar rats and then used this model to compare the effects of an (2C) AR antagonist (ORM-13070 0.3 and 1.0mg/kgs.c.) with an (7) nAChR partial agonist (EVP-6124 0.3mg/kgs.c.) and three atypical antipsychotics (clozapine 2.5mg/kgi.p., risperidone 0.04 and 0.08mg/kgs.c., olanzapine 0.125 and 0.5mg/kgs.c.) on social interaction behavior.ResultsAcute PCP (1.5mg/kgs.c.) produced robust and reproducible deficits in social interaction behavior without affecting locomotor activity. The selective (2C) AR antagonist significantly ameliorated PCP-induced social interaction deficits. In contrast, neither the partial (7) nAChR agonist nor any of the three atypical antipsychotics were able to reverse the behavioral deficits at the selected doses.ConclusionOur findings confirm that (2C) AR antagonism is a potential mechanism for the treatment of the negative symptoms of schizophrenia.